A Glimpse Into The Expert Outlook On Moderna Through 5 Analysts
Portfolio Pulse from Benzinga Insights
In the last three months, 5 analysts have provided diverse ratings on Moderna (NASDAQ:MRNA), with an average 12-month price target of $113.8, reflecting a 44.97% increase from the previous target of $78.50. Moderna's financials show a -45.37% decline in revenue growth and below industry benchmarks in profitability and efficiency metrics. The company's mRNA technology has been validated with its COVID-19 vaccine, and it has 39 mRNA development candidates in clinical trials.
March 28, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's stock might see short-term movements based on the latest analyst ratings and financial performance. The new average price target suggests optimism, but financial challenges could temper gains.
The increase in the average price target to $113.8 indicates a bullish outlook from analysts, which could positively influence investor sentiment and Moderna's stock price in the short term. However, the reported decline in revenue and below-average profitability and efficiency metrics might raise concerns among investors, potentially limiting the stock's upside.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100